These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 16270070)

  • 21. Structural biology of ubiquitin-protein ligases.
    Pavletich NP
    Harvey Lect; 2002-2003; 98():65-102. PubMed ID: 16033158
    [No Abstract]   [Full Text] [Related]  

  • 22. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.
    Jiang H; Ren Y; Zhao J; Feng J
    Hum Mol Genet; 2004 Aug; 13(16):1745-54. PubMed ID: 15198987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its C2 domain.
    Wiesner S; Ogunjimi AA; Wang HR; Rotin D; Sicheri F; Wrana JL; Forman-Kay JD
    Cell; 2007 Aug; 130(4):651-62. PubMed ID: 17719543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tetrahydroberberine blocks ATP-sensitive potassium channels in dopamine neurons acutely-dissociated from rat substantia nigra pars compacta.
    Wu C; Yang K; Liu Q; Wakui M; Jin GZ; Zhen X; Wu J
    Neuropharmacology; 2010 Dec; 59(7-8):567-72. PubMed ID: 20804776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI.
    Huynh DP; Scoles DR; Nguyen D; Pulst SM
    Hum Mol Genet; 2003 Oct; 12(20):2587-97. PubMed ID: 12925569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine and adult neurogenesis.
    Borta A; Höglinger GU
    J Neurochem; 2007 Feb; 100(3):587-95. PubMed ID: 17101030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mtDNA clock runs out for dopaminergic neurons.
    Manfredi G
    Nat Genet; 2006 May; 38(5):507-8. PubMed ID: 16642013
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of repetitive transcranial magnetic stimulation on a model rat of Parkinson's disease.
    Yang X; Song L; Liu Z
    Neuroreport; 2010 Mar; 21(4):268-72. PubMed ID: 20087233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Parkinson's disease: what have we learned from the genes responsible for familial forms?].
    Corti O; Brice A
    Med Sci (Paris); 2003 May; 19(5):613-9. PubMed ID: 12836396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans.
    Zheng Y; Watakabe A; Takada M; Kakita A; Namba H; Takahashi H; Yamamori T; Nawa H
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Jun; 33(4):701-6. PubMed ID: 19336245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A possible role for humoral immunity in the pathogenesis of Parkinson's disease.
    Orr CF; Rowe DB; Mizuno Y; Mori H; Halliday GM
    Brain; 2005 Nov; 128(Pt 11):2665-74. PubMed ID: 16219675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
    Yamada M; Mizuno Y; Mochizuki H
    Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation.
    Inzelberg R; Hattori N; Mizuno Y
    Neurology; 2005 Dec; 65(11):1843. PubMed ID: 16344545
    [No Abstract]   [Full Text] [Related]  

  • 36. Neurophysiology: stressful pacemaking.
    Bean BP
    Nature; 2007 Jun; 447(7148):1059-60. PubMed ID: 17597746
    [No Abstract]   [Full Text] [Related]  

  • 37. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.
    Chung KK; Thomas B; Li X; Pletnikova O; Troncoso JC; Marsh L; Dawson VL; Dawson TM
    Science; 2004 May; 304(5675):1328-31. PubMed ID: 15105460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathogenic mutations inactivate parkin by distinct mechanisms.
    Henn IH; Gostner JM; Lackner P; Tatzelt J; Winklhofer KF
    J Neurochem; 2005 Jan; 92(1):114-22. PubMed ID: 15606901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cystatin C prevents degeneration of rat nigral dopaminergic neurons: in vitro and in vivo studies.
    Xu L; Sheng J; Tang Z; Wu X; Yu Y; Guo H; Shen Y; Zhou C; Paraoan L; Zhou J
    Neurobiol Dis; 2005 Feb; 18(1):152-65. PubMed ID: 15649706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In pursuit of the causes for Parkinson disease].
    Mizuno Y
    Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1761-73. PubMed ID: 16223133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.